Nav: Home

Using precision medicine, researchers discover cause and treatment for specific lung disease

March 07, 2019

(Boston)--Researchers have identified that dysfunction of a specific immune cell, called B cells, underlies lung disease that affects patients with the rare immunological disorder known as common variable immunodeficiency (CVID). Therapeutically targeting these B cells improved the lung disease in all patients they treated. This was the largest study ever conducted for treatment of CVID lung disease.

Primary immunodeficiencies are genetic disorders that predispose a person to infection and immunological disease. CVID is the most prevalent symptomatic primary immunodeficiency and is typically diagnosed in adulthood. In addition to infections, CVID leads to reduced survival and quality of life and is frequently complicated by interstitial lung disease (ILD) that has no known etiology or adequate therapy.

Researchers studied 73 CVID patients and found their levels of immunoglobulin (Ig) M increased when their ILD worsened. This elevation of IgM in the blood reflected the extent of IgM production locally by B cells in the lungs. They then found that by depleting B cells with the drug rituximab they could effectively treat CVID ILD. They also identified a protein that activates B cells known as B cell activating factor (BAFF) that contributes to lung disease recurrence in CVID, which they believe may serve as an additional therapeutic target in the future.

"Because we are able to treat these patients using a precision medicine approach, we can spare them the side effects of more broadly immunosuppressive therapies that have been previously tried in these patients with mixed results," explained corresponding author Paul J. Maglione, MD, PhD, assistant professor of medicine at Boston University School of Medicine (BUSM).

According to the researchers, the ability to identify elevation of immunoglobulin M as a marker of lung disease progression in CVID, allows the physician to know precisely when their patients need treatment without having to wait for their lung disease to decline.

Maglione hopes this study will lead to safer and more potent treatment of lung disease in CVID. He believes it demonstrates that new therapies can continue to emerge through biomedical research and bring hope for illnesses that are difficult to treat, rare, or otherwise poorly understood.
The research was performed while Maglione was on staff at Icahn School of Medicine at Mount Sinai.

These findings appear online in the journal JCI Insight.

Funding for this study was provided by grants from the Primary Immune Deficiency Treatment Consortium, Rare Disease Foundation, NIH grants AI137183 (to PJM) and AI061093 (to CCR) and the Swedish Research Council and Swedish Society of Medicine grant 2015-06486 (to EKG).

Boston University School of Medicine

Related Lung Disease Articles:

Lung cancer screening guidelines do not detect disease among first responders
National lung cancer screening guidelines are inadequate to diagnose patients who contract lung cancer from occupational exposure, including first responders, according to a study reported today at the International Association for the Study of Lung Cancer's North America Conference on Lung Cancer in Chicago.
New drug target discovered for the lung disease PAH
Study suggests that targeting an 'Eyes Absent' protein could lead to better medicine for treating PAH, a deadly lung disease.
In lung disease, crackling and wheezing can be more than just a sign of sickness
Doctors know they're the sounds of lung problems, but it turns out they might be more than symptoms--crackling and wheezing could be the sounds of a disease progressing, a University of Michigan researcher has found.
Lung disease bronchiectasis associated with high frequency of allergy
An international research team led by Nanyang Technological University, Singapore (NTU Singapore) has found that patients with the lung disease bronchiectasis also often display sensitivity to airborne allergens, and has highlighted the particular role that fungi appear to play.
Mucus, cough and chronic lung disease: New discoveries
As a cold ends, a severe mucus cough starts. Sound familiar?
More Lung Disease News and Lung Disease Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...